Pharming develops innovative therapeutics for the treatment of genetic disorders.
Lead product Ruconest for HAE Ruconest™ (Rhucin® in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein.
We also investigate the same recombinant protein in other indications, including antibody-mediated rejection (AMR) and delayed graft function (DGF) following transplantation. Protein technology at Pharming, we have specialized ourselves in the production of protein therapeutics. Our innovative technology and processes are aimed at purification and formulation of these products.
Location Pharming has its headquarters in Leiden, the Netherlands. Pharming employs approximately 170 people.